The study, led by Daniel Arroyo-Sánchez and Oscar Cabrera-Marante of the Immunology Department at Hospital Universitario 12 de Octubre and published in the Journal of Translational Medicine, set out to answer a deceptively simple question: what happens to the B cells of CVID patients when they are pushed to produce antibodies under controlled laboratory conditions? To find out, the researchers isolated peripheral blood mononuclear cells, the mixed population of immune cells circulating in the blood, from 20 patients with CVID and from healthy donors. These cells were then cultured in the laboratory with a carefully chosen cocktail of stimuli: interleukin-2, a cytokine that supports lymphocyte survival and proliferation, and R848, a synthetic compound that activates Toll-like receptors, the molecular sensors that normally alert B cells to microbial invasion and drive them toward antibody-secreting states.

The choice of stimulation is scientifically significant. Toll-like receptor signaling has become an increasingly important focus in immunodeficiency research because it mimics a key pathway used during natural infection and, notably, during vaccination. Recent clinical observations had shown that some CVID patients mount partial responses to mRNA vaccines, hinting that a residue of functional capacity might survive within their B-cell compartment. By combining IL-2 with R848, the team created conditions designed to coax out whatever antibody-producing potential the patients’ cells still possessed, and then to measure precisely how far that potential could carry them.

The results, tracked over a ten-day culture period, revealed a striking temporal pattern. In cultures from healthy controls, antibodies remained readily detectable in the culture supernatants throughout the observation window, a sign that the cells had successfully differentiated into antibody-secreting cells and sustained their output. In cultures from CVID patients, by contrast, the ability to sustain antibody production collapsed. By day 10, the patients’ cultures had failed to maintain antibody secretion, and the cellular composition of those cultures told its own story: a predominance of IgD-CD27- B cells, a subset that lacks the classical markers of activated memory cells and is generally associated with a less mature, less responsive state.

Crucially, the defect was not a simple absence of responsive cells. On day 6 of culture, the proportion of memory B cells in the patients’ cultures was comparable to that seen in healthy controls. This timing matters enormously for interpretation. It suggests that CVID B cells can initially be pushed toward a memory-like phenotype when stimulated through Toll-like receptors in the presence of IL-2, but that this apparent activation cannot be consolidated into durable antibody output. The failure, in other words, appears to lie in the later stages of the differentiation program, in the transition from an activated, memory-like state to a fully functional antibody-secreting plasma cell, rather than in the earliest steps of B-cell activation.

To probe the molecular roots of that failure, the researchers turned to transcriptomic analysis, sequencing the gene expression profiles of the cultured cells. The comparison between patients and healthy controls uncovered a coherent pattern of dysregulation. Genes related to antibody production were expressed at lower levels in the patients’ cells, consistent with the observed collapse in antibody secretion. Genes involved in adhesion and in proinflammatory signaling were also downregulated, pointing to a broader failure of the activated B cell to adopt the full behavioral repertoire of a responding immune cell, including the physical interactions with other immune cells that normally support germinal-center-like reactions in the culture dish.

Perhaps most intriguingly, the patients’ cells showed increased expression of genes associated with immune inhibitory responses. This shift toward an inhibitory program provides a mechanistic explanation for the paradox that has long defined CVID: B cells that are present, sometimes numerous, and capable of at least partial activation, yet chronically unable to deliver protective antibodies. If the cells are actively ramping up inhibitory pathways in response to stimulation, then the defect may not be a passive inability to respond but an active regulatory brake, one that engages precisely when the cells should be committing to antibody production.

The analysis of soluble factors in the culture supernatants reinforced this picture. Compared with healthy controls, the patients’ cultures contained lower concentrations of APRIL, a cytokine that plays a well-established role in supporting B-cell survival and the differentiation of antibody-secreting cells, and lower levels of interferon-alpha, an antiviral cytokine with important immunoregulatory functions. At the same time, the patients’ supernatants showed higher concentrations of BTLA, an inhibitory receptor of the CD28 family that delivers dampening signals to lymphocytes. The combination is telling: the patients’ cultures were simultaneously deprived of positive differentiation signals and enriched for inhibitory ones, a molecular environment stacked against sustained antibody output.

Taken together, the study’s findings sketch a coherent model of B-cell dysfunction in CVID. When stimulated through Toll-like receptors, the cells of these patients can begin the journey toward activation and memory differentiation, but they cannot sustain it. Their gene expression programs drift away from antibody production, adhesion, and inflammation and toward immune inhibition, while their soluble environment loses the supportive cytokines that healthy cultures provide. The researchers suggest that these insights into functional impairment after Toll-like receptor stimulation may be directly relevant to the B-cell dysfunction observed in patients with CVID, and they may help explain why some patients show only partial responses to vaccines that depend heavily on this signaling pathway.

The work also carries practical implications for the future. An in vitro assay that reliably distinguishes the functional profile of CVID B cells from healthy ones could, with further validation, help stratify patients, identify those with residual responsiveness, and guide more individualized approaches to immunoglobulin replacement and vaccination strategies. The study was approved by the Institutional Ethics Committee of Hospital Universitario 12 de Octubre and conducted with written informed consent from all participants, whose willingness to donate blood samples the authors explicitly acknowledged. Funded through Spanish COVID-19 research projects and supported by the genomic analysis group of the Spanish National Cancer Research Centre, the research exemplifies how translational immunology can turn a bedside mystery, why vaccinated patients remain vulnerable, into a bench-side mechanism, one inhibitory signal at a time.

Subject of Research: B-cell functional impairment in common variable immunodeficiency assessed by in vitro Toll-like receptor stimulation

Article Title: Common variable immunodeficiency: B cells' impairment in an in vitro assay

Article References: Common variable immunodeficiency: B cells' impairment in an in vitro assay. (n.d.). https://doi.org/10.1186/s12967-026-08821-8

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08821-8

Keywords: common variable immunodeficiency, B cells, antibody production, Toll-like receptor, R848, interleukin-2, transcriptomics, ELISPOT, flow cytometry, APRIL, BTLA, primary immunodeficiency

The survey gathered 1,167 completed interviews online via SurveyMonkey, with data provided to SSRS for formal analysis in August 2026. Respondents included patients, caregivers, healthcare providers, and patient advocates from around the world, giving the results a breadth that few single-condition studies can match. What emerges is a picture of medical dependence that is both chronic and intimate: roughly two in three respondents reported that they, or someone they care for, receive plasma-derived medicines at least once a month, and 41 percent said treatment occurs weekly. For these families, plasma therapy is not an occasional intervention but a recurring rhythm of life, scheduled around infusions, clinic visits, and the constant logistics of maintaining a supply of medicine that exists only because someone else volunteered to donate.

The conditions that drive this dependence are diverse, but they share a common thread: the body’s own biochemistry has failed in a way that only donated human plasma can reliably correct. Nearly half of respondents said they or someone they care for receive plasma-derived medicines for an immunodeficiency, 18 percent for a bleeding or blood disorder, 16 percent for a neurological condition, and 15 percent for a lung-related illness. Primary immunodeficiencies, a group of more than 400 inherited disorders in which part of the immune system is missing or malfunctioning, are among the most prominent indications. Patients with these conditions lack adequate antibodies of their own, and the immunoglobulin therapies derived from pooled donor plasma effectively replace that missing molecular armor, shielding them from infections that most people shrug off without noticing.

The technical journey from a donor’s arm to a patient’s infusion bag is one of the more remarkable processes in modern biomedicine. Once collected, plasma from thousands of individual donations is pooled and subjected to fractionation, a carefully sequenced separation process that exploits differences in protein solubility and behavior to isolate specific therapeutic components. Immunoglobulins, clotting factors such as Factor VIII for hemophilia, albumin for treating shock and burns, and other proteins are each extracted, purified, and subjected to multiple viral inactivation and removal steps. Because many of these proteins cannot yet be produced synthetically at scale, donated human plasma remains the only practical source. That biological reality is what binds a donor in Addison, Illinois, to a patient on another continent, and it is why the industry built around fractionation is often described as a unique sector of the biologics and biotechnology landscape.

The survey’s most striking finding concerns speed of effect. More than two-thirds of respondents, 69 percent, noticed a change in their health, or in the health of someone they care for, within a few months of beginning a plasma-derived medicine, and 26 percent noticed a change within just a few days. For clinicians who treat immunodeficiency or bleeding disorders, this rapid response is familiar territory: a child with hemophilia who receives a clotting factor concentrate can stop a spontaneous joint bleed within hours, and an immunodeficient patient beginning immunoglobulin replacement often reports a dramatic reduction in the frequency and severity of infections within the first months of therapy. The survey data translate that clinical observation into a population-level statistic, quantifying how quickly these biologics alter the daily experience of illness.

Confidence in the medicines themselves is correspondingly high. Fully 87 percent of patients expressed confidence in the safety and efficacy of plasma-derived therapies, a figure that reflects decades of incremental improvement in donor screening, pathogen detection, and manufacturing controls. Modern plasma products undergo nucleic acid testing for blood-borne viruses, hold periods that allow emerging infections to be detected before pools are released, and redundant viral clearance steps during fractionation. That layered safety architecture, developed and refined since the challenges of the 1980s, underpins the trust that patients report in the survey and allows these therapies to be delivered into veins on a weekly basis with a risk profile that patients and their physicians consider acceptable for lifelong use.

Gratitude emerges as the emotional throughline of the findings. More than three-quarters of respondents, 77 percent, described themselves as grateful to plasma donors, an expression that the survey’s sponsors hope will translate into more people rolling up their sleeves. Behind the statistic are individual stories that illustrate what the numbers mean in practice. Christy Savino, a plasma recipient diagnosed with a primary immunodeficiency, described the impact in personal terms: the therapy allows her family to make memories together, a gift of life she described as present in every moment of every day and traveling with the family wherever they go. Her husband, Antonio Savino, donates plasma regularly at a BioLife Plasma Services donation center in Addison, Illinois, in her honor, a concrete example of the donor-to-patient loop that the awareness week is designed to celebrate.

Patient advocacy organizations see the survey as an opportunity to widen the circle of people who understand where these medicines come from. Jorey Berry, President and CEO of the Immune Deficiency Foundation, noted that this year’s International Plasma Awareness Week campaign shines a light on people and families living with immunodeficiencies and other rare diseases, and emphasized that for many patients these medicines are not merely treatments but what makes everyday life possible. His message to potential donors is direct: every plasma donation matters deeply, and donating offers healthy people a tangible way to give patients the chance to live healthier, fuller lives. The campaign’s framing, that plasma powers possibility, is an attempt to convert abstract appreciation into the specific act of booking a donation appointment.

The scale of the enterprise behind these therapies is easy to underestimate. The Plasma Protein Therapeutics Association, which represents the manufacturers and collectors of plasma protein therapies, counts more than 1,000 plasma collection centers across North America and Europe among its members. Those members produce approximately 80 percent of the plasma protein therapies used in the United States and approximately 60 percent of those used in Europe. Meeting global demand requires millions of donations each year, because a single patient’s annual immunoglobulin supply can require donations from hundreds or even thousands of individual donors over the course of a year of fractionated production. The arithmetic of that supply chain explains why donor recruitment is a permanent, global public health effort rather than a one-time campaign.

For the patients and caregivers who answered the survey, the message that emerges is one of quiet, ongoing dependence paired with remarkable resilience. The age at which treatment began varied widely among respondents, though the largest share, 49 percent, said they or someone they care for first received a plasma-derived medicine between the ages of 36 and 64, indicating that these therapies enter lives at every stage, not only in childhood. What unites them is the experience of a medicine that works quickly, is trusted deeply, and exists only through the generosity of strangers. International Plasma Awareness Week, which runs through the week beginning October 5, asks the public to see that connection clearly: behind every vial of immunoglobulin or clotting factor is a person who took an hour to donate, and behind every donor is a patient whose ordinary day, and ordinary family memories, depend on it. Information about donation and patient stories is available at plasmaweek.org and through the association’s donation center locator.

Subject of Research: Global patient survey on the use, impact, and perceived safety of plasma-derived medicines and the role of plasma donors

Article Title: New global survey shines a light on the patients who rely on plasma-derived medicines—and the donors who make them possible

Article References: New global survey shines a light on the patients who rely on plasma-derived medicines—and the donors who make them possible. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: plasma donation, plasma-derived medicines, plasma protein therapeutics, primary immunodeficiency, immunoglobulin therapy, bleeding disorders, International Plasma Awareness Week, patient survey, SSRS, PPTA, fractionation, rare diseases

The three conditions covered by the analysis share a common therapeutic backbone despite their very different origins. Primary immunodeficiencies are rare, chronic disorders caused by inherited genetic mutations that impair the immune system’s ability to produce functional antibodies, often manifesting in infancy or early childhood, though diagnosis can be delayed well into adulthood. Italy maintains a well-established registry and clinical network for these conditions, with national data indicating a prevalence of between 0.002 and 0.006 percent. Secondary immunodeficiencies, by contrast, arise from external factors such as malignancies, infections, major surgeries, or immunosuppressive therapies, leaving patients vulnerable to serious infections and imposing significant psychological and economic burdens. Chronic inflammatory demyelinating polyneuropathy, or CIDP, is a rare autoimmune neurological disorder in which immune-mediated destruction of the myelin sheath surrounding peripheral nerves causes progressive motor and sensory deficits, with an estimated incidence of 0.36 cases per 100,000 people per year.

For all three patient groups, long-term immunoglobulin therapy is a cornerstone of management, either to replace missing antibodies or to modulate aberrant immune activity. Traditionally, this therapy has been delivered intravenously in hospital or infusion-center settings, an approach that consumes scarce outpatient capacity and imposes repeated travel and time costs on patients. Subcutaneous immunoglobulin offers an alternative that patients can self-administer at home, but the conventional vial-based format requires manual preparation, including drawing up doses and handling residual volumes, which introduces the risk of contamination and dosing errors while generating product wastage and additional administration time.

IgPro20 stands out as the only subcutaneous immunoglobulin therapy currently available in both vial and pre-filled syringe formats. The pre-filled syringe eliminates the need for manual preparation and dose calculation entirely, shortening infusion times, reducing the risk of errors and contamination, and minimizing leftover product. Real-world evidence suggests these operational advantages translate into measurable clinical and economic benefits: use of the pre-filled syringe has been associated with a 17 percent lower weekly dose compared with vials, a difference the study authors attribute to reduced wastage and more efficient use of immunoglobulin supplies rather than any indication-specific treatment effect. Patient preference data also favor the subcutaneous route, with one study reporting that 73 percent of patients preferred it over intravenous administration.

To quantify the financial implications, the research team built a population-based budget impact model in Microsoft Excel from the perspective of the Italian National Health Service, comparing a current scenario without the pre-filled syringe against a future scenario in which it becomes available. The model incorporated drug acquisition costs, administration fees, and adverse event costs over a three-year horizon. In the first year, an estimated 4,794 patients were eligible for immunoglobulin therapy across the three indications: 1,849 with primary immunodeficiency, 1,439 with secondary immunodeficiency, and 1,505 with CIDP, with annual growth projections of 7 percent for the first and third groups and 12 percent for the second. The comparator basket included ten intravenous immunoglobulin products and five subcutaneous products, with market shares informed by Italian affiliate data. Intravenous infusions were assigned a flat fee of €11.60 per administration under national tariff code 99.14.1, while home-based subcutaneous therapy was assumed to incur no administration cost, since manufacturers in Italy typically provide pumps and training free of charge.

The headline finding is striking: introducing IgPro20 pre-filled syringes was associated with total cost savings of €31,524,488 over three years for the Italian healthcare system. The savings were not evenly distributed across the three conditions. CIDP accounted for the largest share at €17,271,412, reflecting high baseline use of IgPro20 vials and the substantial treatment burden associated with hospital-based administration in this population. Primary immunodeficiency generated savings of €8,840,041, largely through decreased use of vials and other subcutaneous products, while secondary immunodeficiency contributed €5,413,035, driven by reduced intravenous immunoglobulin and vial usage. By cost category, the bulk of the savings came from reduced drug acquisition costs, with additional efficiencies in administration and lower adverse event costs, since subcutaneous therapy is generally associated with lower rates of systemic and serious adverse events than intravenous infusion.

The robustness of these findings was tested through extensive sensitivity and scenario analyses. A one-way sensitivity analysis varying each major parameter by plus or minus 20 percent revealed that the model was most sensitive to the prices of the pre-filled syringe and vials: shifting the syringe price between €52.00 and €78.00 produced a budget impact ranging from a saving of €60.7 million to €2.3 million. Scenario analyses proved reassuring even under conservative assumptions. When the dosing advantage was halved to an 8.5 percent reduction, projected savings fell to €16.6 million but remained substantial. Most notably, even when the researchers assumed identical dosing between the syringe and vial formats, thereby removing the entire 17 percent efficiency advantage drawn from real-world data, the pre-filled syringe still generated savings of €1.6 million over three years. Adopting a broader societal perspective that included indirect costs such as travel and lost productivity increased savings to €31.8 million, while applying lower intravenous product pricing based on regional tenders still yielded €29.9 million in savings. Excluding intravenous-specific infusion complications barely changed the picture, with savings of €31.4 million, confirming that acquisition costs, not adverse event differences, were the primary economic driver.

The study’s authors place these results in the context of a healthcare system under strain. Hospital overcrowding remains a persistent challenge in Italy, and shifting immunoglobulin delivery away from hospital infusion centers toward home-based subcutaneous administration could relieve pressure on inpatient and outpatient services alike. The pre-filled syringe format, by simplifying preparation and supporting patient autonomy, may also improve adherence and quality of life, offering continuity of care even during service disruptions. The authors caution, however, that the choice of therapy and route of administration should remain individualized: some patients prefer intravenous immunoglobulin for its less frequent dosing, direct professional support, or a desire to avoid self-infusion responsibilities, making shared decision-making essential.

The analysis is not without limitations. The model relied on proprietary internal data for population estimates and market shares, which may limit external replicability, and the pivotal 17 percent dosing-reduction assumption was drawn from observational evidence in non-Italian settings. The absence of published adverse event data for subcutaneous immunoglobulin in secondary immunodeficiency led to an assumption of zero events, potentially underestimating costs, and aggregating three clinically distinct populations may obscure meaningful differences in resource use. The model also used a simplified population structure that did not account for aging or mortality, and ex-factory prices may not reflect regional tender variations. Nevertheless, the consistency of savings across every scenario tested lends considerable weight to the central conclusion.

For Italian policymakers and payers, the message is clear: a relatively modest packaging change, moving from vials to pre-filled syringes for subcutaneous immunoglobulin, could free up €31.5 million over three years while supporting a more patient-centered, resource-efficient model of care. As demand for immunoglobulin therapy continues to rise and infusion capacity remains constrained, the study offers actionable evidence that aligning clinical value with economic sustainability is achievable, one syringe at a time.

Subject of Research: Budget impact analysis of subcutaneous immunoglobulin pre-filled syringes for immunodeficiency and CIDP in Italy

Article Title: Multi-Indication Budget Impact Analysis of Subcutaneous IgPro20 Pre-filled Syringes for the Treatment of Primary Immunodeficiency Syndromes, Secondary Immunodeficiencies, and Chronic Inflammatory Demyelinating Polyneuropathy in Italy

Article References: Kuatov, B., MacDonald, A., Priest, S., Tran, D., Undreiner, L., Taskin, M. I., Villa, S., & Marcellusi, A. (2026). Multi-Indication Budget Impact Analysis of Subcutaneous IgPro20 Pre-filled Syringes for the Treatment of Primary Immunodeficiency Syndromes, Secondary Immunodeficiencies, and Chronic Inflammatory Demyelinating Polyneuropathy in Italy. Advances in Therapy. https://doi.org/10.1007/s12325-026-03805-y

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03805-y

Keywords: immunoglobulin therapy, pre-filled syringes, primary immunodeficiency, secondary immunodeficiency, CIDP, budget impact analysis, health economics, Italy, subcutaneous immunoglobulin, IgPro20, healthcare costs, home-based treatment